A Phase 4 interventional study of Brain Imaging with [Cu64]DOTATATE and Radio-guided Surgery With Neoprobe Utilization in Meningioma, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.
Among the 129 studies in Meningioma with a site in United States, this one is the 74th largest by planned enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2024, is one of 2 in phase 4, reaches primary completion later than 8 of the 37 other live ones, and was the 118th registered.
256 studies on the registry are indexed under Meningioma; 86 are open to participants now.
Browse Meningioma studies →27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18+
Eben Rosenthal · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
Joshua Palmer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 55 · Phase 3 6 · Phase 4 2
First in 1992; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 180 interventional studies indexed under Meningioma.
Median enrollment 30 across the 107 interventional studies, 106 across the 14 observational. Of the 82 that completed or were terminated, 31 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 129 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Weill Medical College of Cornell University has 4 studies filed under Meningioma — fewer than ten, so there is no comparison to draw.
14 of the studies in Meningioma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03180268Phase 3NRG OncologyObservation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | 2027-06-15 |
| NCT05425004Baptist Health South FloridaCabozantinib for Patients With Recurrent or Progressive Meningioma | 2026-12 |
| NCT04087902Ohio State UniversityLong-Term Longitudinal QoL in Patients Undergoing EEA | 2026-12-31 |
| NCT07150806Joshua PalmerRYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | 2026-12-31 |
| NCT06377371Weill Medical College of Cornell UniversityFeasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE | 2027-01 |
Add all 14 to your calendar (.ics) → With an account.
Among the 129 studies in Meningioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study team hypothesizes that it is feasible to intraoperatively detect tumor following [CU64]DOTATATE injection using the gamma probe device.
Objectives:
Primary objectives: The primary objective of this pilot study is to evaluate the feasibility of intraoperative tumor detection using [Cu64]DOTATATE. The study team further wants to validate the gamma count measurements using pre- and post-operative Positron Emission Tomography (PET) standardized uptake value (SUV) .
Secondary Objectives: To correlate intraoperative tracing findings with from pathology markers ( World Health Organization grade (WHO grade), Ki-67, Somatostatin Receptor 2 expression (SSTR2A expression), Estrogen receptor expression (ER expression), Progesterone receptor expression (PR expression)) using samples obtained as part of routine surgical care. To evaluate the correlation of post resection gamma count with longitudinal PET follow up.
Exploratory objectives: To establish best practices for integration of intraoperative tumor tracing using the neoprobe into the surgical workflow. To determine surgical candidates who will benefit most from intraoperative tracing based on tumor location, MRI features, etc.
Overall Design:
This is a single-center prospective observational pilot study to determine the feasibility of using [Cu64]DOTATATE for intraoperative tumor detection. 20 patients diagnosed with meningioma by conventional magnetic resonance imaging (MRI) who are candidates for surgical resection will be enrolled. Enrollment will be facilitated by colleagues in the neurosurgery department (also co- investigators on this study) with whom the PI has had several years of collaboration and an ongoing referral stream (6pprox.. 5 patients per week).
Patients will subsequently undergo pre-operative [Cu64]DOTATATE PET/MRI 12-24 hours prior to surgery. Given that [Cu64]DOTATATE has a much longer half-life compared to [Ga68]DOTATATE, it is uniquely suited for this application, allowing the patient to be injected once with the clinically approved dose, undergo immediate Positron Emission tomography scan and magnetic resonance imaging scan (PET/MRI) or Positron Emission tomography scan and computed tomography scan (PET/CT), and undergo resection the following day with sufficient radiotracer in situ for radio-guided surgery (RGS).
During the operation, the neurosurgeon will make a number of measurements using the neoprobe (available at our institution and currently in frequent routine clinical use for intraoperative sentinel node detection; commonly used for breast cancer, melanoma, oral cancer):
These steps will not alter the regular course of the surgery in any way. Patients will have two follow-up points after the surgery: 1) at 6 weeks to 3 months post-op and 2) at 6 months to 12 months post-op. Patients will be clinically examined and will undergo repeat [Cu64]DOTATATE PET/MRI or PET/CT during these follow up visits, as standard of care, with radiotracer dosage being funded by the study for the 1st follow up scan, and determined standard of care for the 2nd follow up scan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A diagnostic intervention in which patients will undergo intraoperative meningioma tracing using \[Cu64\]DOTATATE.
Diagnostic Test: Brain Imaging with [Cu64]DOTATATE · Procedure: Radio-guided Surgery With Neoprobe Utilization
Patients will undergo a \[Cu64\]DOTATATE PET/MRI or PET/CT before undergoing radio- guided surgery. Patients will undergo another \[Cu64\]DOTATATE PET/MRI or PET/CT 6 weeks- 3 months after their surgery, and 6 months- 12 months after surgery.
After the subjects undergo the preoperative \[Cu64\]DOTATATE PET/MRI, subjects will undergo radio-guided surgery in which the surgeon will utilize a standard intraoperative gamma probe (Neoprobe Gamma Detection System ®) to assess primary/residual tumor detection.
Preoperative [Cu64]DOTATATE PET SUV
preoperative lesion \[Cu64\]DOTATATE PET SUV
Time frame: At time of enrollment
1st Post-operative [Cu64]DOTATATE PET SUV
6 weeks to 3 months follow up post operative \[Cu64\]DOTATATE PET SUV
Time frame: 3 months
2nd Post-operative [Cu64]DOTATATE PET SUV
6 months to 12 months follow up post operative \[Cu64\]DOTATATE PET SUV
Time frame: 1 year
MRI Size Measurements
preoperative size measurements based on Response Assessment in Neuro-Oncology (RANO) guidelines
Time frame: At time of enrollment
GTR vs STR Assessment
postoperative MRI-based assessment of GTR versus STR by a neuroradiologist, as determined by the presence or absence of nodular dural-based enhancement on post contrast 3D T1-weighted MR imaging and direct comparison to preoperative MRI.
Time frame: 6 weeks- 3 months
MRI Progression Assessment
follow-up MRI assessment of progression based on RANO guidelines
Time frame: 6-12 months
Target Lesion Neoprobe Count
Neoprobe count of the target lesion prior to resection.
Time frame: At time of enrollment
Subtotal Neoprobe Count
Neoprobe count of the subtotally resected tumor or the resection cavity in case of presumed GTR post resection.
Time frame: At time of enrollment
Reference Background Neoprobe Count
Neoprobe count of the reference background measured at least 1 cm away from the tumor (measured in at least two locations depending on the operative field)
Time frame: At time of enrollment
SSTR2 expression
immunohistochemistry analysis of SSTR2 expression in the resected tumor
Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).
WHO grade
determined histomorphologically based on pathologist's assessment of resected tumor tissue.
Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).
Ki67 Proliferation Index
Ki67 Proliferation Index (percentage of positively stained tumor cells among the total number of malignant cells assessed).
Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).
ER/PR expression
determined based on pathologist's assessment of resected tumor tissue.
Time frame: At time of clinical neuropathological evaluation of resected tumor tissue (Immediate postoperative setting).
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Jan 2027, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →